{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&_metadata=all&max-answer.dateOfAnswer=2019-05-22", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&_page=0&max-answer.dateOfAnswer=2019-05-22", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "items" : [{"_about" : "http://data.parliament.uk/resources/773568", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/773568/answer", "answerText" : {"_value" : "

Anyone suffering ill health deserves access to appropriate clinical investigation and care, and to be treated with dignity and respect. This is an important responsibility of doctors and other healthcare providers.<\/p>

The Medicines and Healthcare products Regulatory Agency takes every report of a suspected adverse reaction seriously and has closely evaluated the safety of the human papillomavirus vaccine since the vaccination programme was introduced in the United Kingdom in 2008. All reports, including any submitted by patients and their families, are kept under continual review to identify potential new risks.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2017-11-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-11-01T12:47:48.597Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-10-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what steps they are taking to ensure that the families of children believed to have suffered serious adverse reactions to human papilloma virus vaccinations are treated with the same levels of dignity and respect accorded to families whose children have other medical conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL2283"} , {"_about" : "http://data.parliament.uk/resources/600530", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/600530/answer", "answerText" : {"_value" : "

The Environment Agency (EA) has recently restructured its senior management team following a voluntary exit scheme and has filled all vacancies within the Energy Saving Opportunity Scheme (ESOS) senior team.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4284", "label" : {"_value" : "Biography information for Baroness Neville-Rolfe"} } , "answeringMemberPrinted" : {"_value" : "Baroness Neville-Rolfe"} , "dateOfAnswer" : {"_value" : "2016-10-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-10-19T13:26:25.943Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2016-10-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Energy: Conservation"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what steps they are taking to fill senior management vacancies on the Energy Savings Opportunity Scheme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/621", "label" : {"_value" : "Biography information for Lord Moonie"} } , "tablingMemberPrinted" : [{"_value" : "Lord Moonie"} ], "uin" : "HL2283"} , {"_about" : "http://data.parliament.uk/resources/419210", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/419210/answer", "answerText" : {"_value" : "

Ensuring that the National Health Service is able to support the availability and use of effective medicines for cancers, including rare blood cancer, is a key priority.<\/p>

<\/p>

<\/p>

<\/p>

Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. The Taskforce published its report, Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020<\/em>, in July, and made many recommendations relevant to rarer and blood cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments. NHS England, Public Health England and other healthcare organisations are now considering the detail of the individual recommendations.<\/p>

<\/p>

<\/p>

<\/p>

Earlier in 2015, NHS England consulted on the principles and process by which it makes investment decisions in specialised services, which address the issue of rarity. The outcome of future investment decisions taken by NHS England will be published in accordance with the new process. NHS England\u2019s response to the consultation is attached, and can be found at:<\/p>

<\/p>

<\/p>

<\/p>

https://www.england.nhs.uk/commissioning/spec-services/key-docs/<\/a><\/p>

<\/p>

<\/p>

<\/p>

<\/p>

<\/p>

In addition to drug treatments for blood cancers, NHS England also commissions blood and bone marrow transplantation in accordance with its current published policy. A revision of the policy is planned during 2015-16 to be implemented during 2016-17. The current published policy is attached, and can be found at:<\/p>

<\/p>

<\/p>

<\/p>

http://www.england.nhs.uk/wp-content/uploads/2013/04/b04-p-a.pdf<\/a><\/p>

<\/p>

<\/p>

<\/p>

The National Institute for Health and Care Excellence is developing guidelines for the treatment of multiple myeloma and these are currently subject to public consultation.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "attachment" : [{"_about" : "http://data.parliament.uk/resources/419210/answer/attachment/1", "fileName" : {"_value" : "nhse-respns-publictn-17-06-15.pdf"} , "title" : "NHS England consultation response"} , {"_about" : "http://data.parliament.uk/resources/419210/answer/attachment/2", "fileName" : {"_value" : "b04-p-a (1).pdf"} , "title" : "Transplantation policy April 2013"} ], "dateOfAnswer" : {"_value" : "2015-09-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-09-22T10:22:16.537Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-09-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Blood Cancer"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what the Department of Health is doing to prioritise the availability of treatments for rare blood cancers, such as multiple myeloma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL2283"} , {"_about" : "http://data.parliament.uk/resources/100077", "AnsweringBody" : [{"_value" : "Foreign and Commonwealth Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100077/answer", "answerText" : {"_value" : "We are concerned to hear that a Pakistan court has upheld the imposition of the death penalty in the case of Asia Bibi. We support the EU's recent statement of concern and hope that the verdict will be overturned on appeal. We regularly raise at the highest levels the misuse of blasphemy laws in Pakistan both against Muslims and against religious minorities. We have consistently pressed the Government of Pakistan on the issue of the death penalty and expressed our principled opposition to it in all cases. We will continue to raise these issues."} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3474", "label" : {"_value" : "Biography information for Baroness Anelay of St Johns"} } , "answeringMemberPrinted" : {"_value" : "Baroness Anelay of St Johns"} , "dateOfAnswer" : {"_value" : "2014-11-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-11-04T17:14:45.380975Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "16"} , "answeringDeptShortName" : {"_value" : "Foreign and Commonwealth Office"} , "answeringDeptSortName" : {"_value" : "Foreign and Commonwealth Office"} , "date" : {"_value" : "2014-10-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pakistan"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what is their assessment of the position of Ms Asia Bibi, a Christian mother of four sentenced to death in Lahore under Pakistan's blasphemy laws; and whether they intend to make representations to the government of Pakistan.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1137", "label" : {"_value" : "Biography information for Lord Patten"} } , "tablingMemberPrinted" : [{"_value" : "Lord Patten"} ], "uin" : "HL2283"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }